SyntekaBio, Inc. (KOSDAQ:226330)

Market Cap	57.37B -50.1%
Revenue (ttm)	3.43B +2,736.7%
Net Income	-17.38B
EPS	-1,115.48
Shares Out	24.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	182,900
Open	2,470.00
Previous Close	2,420.00
Day's Range	2,300.00 - 2,470.00
52-Week Range	2,240.00 - 8,470.00
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 3, 2026

About SyntekaBio

SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was ...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 226330

Financial Performance

In 2025, SyntekaBio's revenue was 3.43 billion, an increase of 2736.72% compared to the previous year's 120.89 million. Losses were -17.38 billion, 140.9% more than in 2024.